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1. Introduction 
Proteolytic cleavage of 9-10 S estrogen receptors 
by endogenous enzymes present in extracts of human 
breast carcinoma and myometrium is inhibited by 
leupeptin and molybdate [ 1,2]. Both agents appear to 
protect the receptor to a similar degree [ 1,2]. Leu- 
peptin is a known inhibitor of serine and thiol pro- 
teases [3], while molybdate has been reported to 
effectively restrict phosphatase activity [4]. Studies 
with breast tumour cytosol [l] and calf receptor 
extracts [5] have implicated respectively, plasminogen 
activators and a Ca2+-activated protease in estrogen 
receptor modification. This paper describes the Ca2+ 
mediated prevention of estrogen receptor stabilization 
by leupeptin and molybdate and provides evidence 
that the mode of molybdate inhibition of hydrolytic 
enzyme activity may be partly due to its ability to 
remove endogenous Ca2+ by precipitation. 
2. Materials and methods 
Human myometrial tissue, frozen in liquid nitrogen, 
was pulverized for 40 s in a microdismembrator 
(Braun, Melsungen). The tissue powder was suspended 
in ice-cold TloDl buffer (tissue:buffer, 1:2) contain- 
ing 10 mM Tris-HCl (Sigma, St Louis MO) and 1 mM 
dithiothreitol (Calbiochem, Carlingford) at pH 7.4 or 
PloDI buffer containing 10 mM potassium dihydrogen 
orthophosphate (Ajax Chemicals, Sydney) and 1 mM 
dithiothreitol at pH 7.4. Cytosol was isolated as in 
[6]. Estrogen receptors in the cytosols were manipu- 
lated by the addition of varying concentrations of 
sodium molybdate (Mallinckrodt, St Louis MO), 
leupeptin (Peptide Institute, Protein Research Foun- 
dation, MinohShi, Osaka), EDTA-ethylenediamine 
tetraacetic acid disodium salt (British Drug Houses, 
Boronia) and CaClz (Ajax Chemicals) to the buffer 
prior to tissue suspension or after cytosol had been 
isolated. Sodium azide (Ajax Chemicals, 0.02%, w/v) 
was present in all buffers. Prior to density gradient 
centrifugation estrogen receptors were labelled with 
5 nM [3H]estradiol-17fl (54 Ci/mmol, Radiochemical 
Centre, Amersham) after incubation at 4°C for 2 h. 
Free and loosely bound labelled hormone was removed 
by treatment with the pellet from an equal volume of 
a dextrancoated charcoal suspension (1% charcoal, 
Norit A, Pfanstiehl; 0.1% dextran T4,,, Pharmacia, 
Lane Cove in 10 mM Tris-HCl buffer (PH 7.4)) over 
20 min at 4°C. Aliquots (200 ~1) of the labelled 
extracts were layered on 20-50% (v/v) glycerol gra- 
dients prepared in TloDl or PloDI buffer. All gradients 
were centrifuged in an MSE-75 Ultracentrifuge at 
145 000 X g for 16 h at 4°C using a titanium swing- 
out rotor. Aldolase (rabbit muscle, Serva, Heidelberg) 
and ovalbumin (Serva) were used as markers. 
3. Results 
The inclusion of Ca2+, in cytosols and density gra- 
dients, completely negated the stabilizing influence 
ofleupeptin and molybdate on the 9 S estrogen recep- 
tor from human myometrial cytosols and produced a 
4 S binding entity exclusively (fig.1). This effect of 
Ca2+ was initially observed with 10 mM leupeptin in 
Tris-buffered cytosols containing 100 mM Ca2+, but 
was subsequently shown to occur with as low as Ca2+ 
5 mM (fig.1). 
When cytosol was preincubated with 50 mM molyb- 
date or leupeptin and then made IO mM with respect 
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Fig.1. Sedimentation analysis of estrogen receptors in the 
presence of protease inhibitors, with or without excess Cal+. 
(A) Cytosols from the same tissue powder in T,,D, buffer 
containing 10 mM molybdate, with (o-o) or without 
(e-o) 5 mM CaCl,, were labelled with [3H]estradiol and 
subjected to glycerol gradient centrifugation i T,,D, buffer 
containing 5 mM CaCl, and T,,D, buffer, respectively. (B) 
Experiments with 10 mM leupeptin were carried out in the 
same way. Sedimentation markers: (A) aldolase (7.9 S) and 
(0) ovalbumin (3.6 S). 
to Ca*+ the extent of 9-4 S receptor conversion was 
markedly decreased (fig.2). The inhibition was most 
pronounced with molybdate where 77% of receptor- 
bound [3H]estradiol in the 9 S region was retained 
after Ca*+ addition (fig2a). In the corresponding 
experiment with leupeptin, carried out on a different 
segment of the same tissue, the 9 S receptor in the 
leupeptin plus Ca*+ cytosol was stabilized to 48% of 
the leupeptin only control (fig2b). A considerable 
decrease in total receptor-bound [3H]estradiol was 
observed in the gradients from cytosols containing 
leupeptin compared to the unprotected extract, to 
which Ca*+ alone had been added (fig2b). A similar 
decrease with molybdate was not apparent (fig2a). 
From fig.l,2 it is evident that although 9 S receptor 
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Fig.2. The influence of exogenous CaZ+ on the sedimentation 
profile of estrogen receptors pre-stabilized by molybdate and 
leupeptin. (A) Molybdate (50 mM) was added to an aliquot 
of freshly prepared myometrial cytosol in T,,D, buffer. After 
15 mm at 4°C CaCl, (10 mM) was added to the molybdate 
free cytosol and a portion of the cytosol containing the inhib- 
itor. The resulting cytosols in T,,D, with 10 mM Ca’+ 
(A----n), T,,D, with 50 mM molybdate (e-o) and T,,D, 
with 50 mM molybdate and 10 mM Caa+ (o-o) were 
labelled with [sHIestradio and subjected to glycerol gradient 
centrifugation in T,,D, buffer. (B) Experiments with 50 mM 
leupeptin, using a different segment of the tissue processed 
in (A) were done in the same way. 
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Fig.3. Comparison of sedimentation profiles of estrogen 
receptors from cytosols prepared in P,,D, (e-e). T,,D, 
(A.-A) and T,,D, buffer containing 1.5 mM EDTA 
(o-o). The cytosols were prepared from the same tissue 
used for the experiments described in fig.2 and after labelling 
with [sHIestradio were subjected to glycerol gradient cen- 
trifugation in the corresponding buffers. 
stability is enhanced by molybdate and leupeptin the 
smaller 4 S form is present in at least equal amount 
even at the relatively high inhibitor concentrations of 
50 mM. The requirement of Ca’+ for 9-4 S receptor 
conversion and the rare occurrence of the large recep- 
tor form in Tris-buffered cytosols in the absence of 
protease inhibitors [ 1,221 suggested that there may be 
sufficient calcium of cellular origin to permit receptor 
modification. Molybdate readily precipitates Ca*+ 
from aqueous solution. This property and the ability 
of molybdate as against equal concentrations of leu- 
peptin, to more effectively preserve the 9 S estrogen 
receptor indicate that molybdate may, to some extent, 
inhibit proteolytic activity by restricting the amount 
of Ca*+ available for calcium-dependent protease acti- 
vation [ 5,7]. This mechanism of action for molybdate 
was supported experimentally. From the same tissue 
used to generate the results for fig.2 cytosols were 
prepared in PreDr, TroDI and TroDi buffer containing 
1.5 mM EDTA. Density gradient centrifugation of 
each cytosol on gradients prepared in the correspond- 
ing buffer revealed that the peak height based 9 S:4 S 
ratio was highest for the phosphate buffer (0.89) fol- 
lowed by Tris-buffer with EDTA (0.67) and then 
TrcDr (0.3 1). Phosphate also removes Ca*+ by precip- 
itation, while EDTA is a potent chelator of Ca*+ and 
other divalent cations. An adverse ffect on receptor- 
[3H]estradiol complex formation was noted with 
10 mM EDTA in TreDr buffer. 
4. Discussion 
In [5] the 8.6 S estrogen receptor in calf uterine 
cytosol was cleaved to a smaller 4 S unit by the 
‘receptor-transforming factor’ - a protease which is 
activated by Ca*+ under conditions of high ionic 
strength. Ca*+-Activated proteases have been described 
which catalyze the limited hydrolysis of the proges- 
terone receptors in chick oviduct [8] and the gluco- 
corticoid receptors in mouse mammary tumour [9] 
and rat kidney [lo]. These results indicate that a 
similar Ca*+-dependent enzyme exists in human 
myometrial cytosol and can modify the 9 S estrogen 
receptor after being activated by exogenous Ca*+ or 
endogenous Ca*+ in Tris-buffered myometrial homog- 
enates. The larger receptor form is stabilized by molyb- 
date and leupeptin [ 1,2], but if excess Ca*+ is present 
this protective effect is abolished. Receptor conversion 
catalyzed by exogenous Ca*+ was largely prevented 
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by preincubation with excess molybdate. Leupeptin 
was less able to counter the Ca’+-activated protease, 
even at concentrations 5-times that of added Ca*+. 
Contrary to this, in [9] higher Mr progesterone recep- 
tors were reported stabilized by 10 and 50 mM leu- 
peptin in chick oviduct extracts containing 0.1 M 
CaCl,. The same group [ 1 l] has also indicated that 
inhibition of the proteolytic breakdown of rat kidney 
glucocorticoid receptors by leupeptin is partially 
reversible. These comparisons suggest hat there may 
be some differences in the nature of hydrolytic activ- 
ity to which each receptor system has been exposed. 
The decreased estradiol binding capacity of myo- 
metrial extracts to which 50 mM leupeptin had been 
added confirmed earlier observations with a number 
of human breast tumours [2]. Decreased binding levels , 
with leupeptin were reported [l] and the loss attributed 
to foaming during homogenization and increased ionic 
strength. Our preparations were in hypotonic buffers 
and displayed little tendency to foam either with or 
without leupeptin. The consistent observation of an 
estradiol-receptor complex sedimenting in the 4 S 
region, even at high protease inhibitor concentration, 
may indicate that at least some 9 S receptor was mod- 
ified by cytoplasmic proteases. However, the presence 
of a native 4 S estrogen receptor, distinct from the 
proteolysed form. is also a possibility. A native 4 S 
receptor which combines specifically with a cytoplas- 
mic component to give an 8 S estradiol binding unit 
under hypotonic conditions has been described for 
cow uterus [ 121. 
The increased stability of the 9 S estrogen receptor 
in cytosols containingmolybdate, as well as in extracts 
containing phosphate and EDTA, suggests that molyb- 
date prevents receptor modification, at least partly, 
by removing Ca*+ from solution, thus restricting Ca*+- 
dependent protease activity. Phosphatase inhibition 
by molybdate [4] may also be important for receptor 
stabilization. This dual mode of action by molybdate 
is supported by observations that 9 S receptor con- 
centration was increased, at the expense of the 4 S 
binding unit, when molybdate was added to phosphate- 
buffered cytosols in which the activity of the Ca*+- 
dependent protease would already have been restricted 
(T. R., A. M. S., R. H., unpublished). The presence in 
rat liver of 2 different receptor modifying enzymes, 
one inhibited by leupeptin or antipain and the other 
by phosphoramidon or molybdate has been reported 
1101. 
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